Terazosin (hydrochloride dihydrate)

Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

Product Specifications

CAS Number

[70024-40-7]

UNSPSC

12352005

Hazard Statement

H302

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Endocrinology; Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Terazosin-hydrochloride-dihydrate.html

Purity

99.93

Solubility

DMSO : 31.25 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4.O.Cl.O

Molecular Formula

C19H30ClN5O6

Molecular Weight

459.92

Precautions

H302

References & Citations

[1]Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16 (1) :21-8.|[2]Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90 (5) :1763-8.|[3]Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48 (4) :300060520904851.